Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luarprofen is an innovative inhaled and nebulizable pharmaceutical formulation of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), developed by Química Luar SRL and CEPROCOR. It is designed for the potential treatment of pulmonary affections, particularly to reduce the severity and progression of lung injury and inflammation in patients with severe acute respiratory syndrome due to SARS-CoV-2 (COVID-19). Ibuprofen exerts its therapeutic effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, COX-1 and COX-2, thereby decreasing the synthesis of prostaglandins which are key mediators of inflammation, pain, and fever.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Luarprofen.